If you have spent years trying to get a PCOS diagnosis — or years being told your symptoms were normal, your cycles were just irregular, your weight was the problem — the news that the condition is being renamed may land differently than it does for anyone who hasn’t been through that.
Polycystic ovary syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome — PMOS. The change follows a landmark global consensus study published today in The Lancet, involving more than 50 patient and professional organisations and input from 22,000 people over 11 years. It is not a cosmetic update. It reflects a fundamental shift in how the medical and scientific community understands what this condition actually is.
For the women who knew something was wrong long before anyone believed them, it is also an acknowledgement that was a long time coming.
Why the name mattered — and why it was wrong
The original name — polycystic ovary syndrome — was built around what could be seen on a scan. Cysts on the ovaries. Visible, measurable, nameable.
But the cysts were never the condition. They were a consequence of it. The underlying driver is a complex hormonal and metabolic disruption — affecting how the body processes glucose, regulates hormones, manages inflammation and responds to reproductive signals. The ovarian cysts that gave the condition its name are one downstream effect of a systemic dysfunction that touches almost every system in the body.
Naming it after the cysts was like diagnosing the smoke and missing the fire. It described a symptom and missed the mechanism entirely.
That misidentification had consequences. Women without visible cysts on their scans were told they didn’t have PCOS — despite having every other marker. Women with irregular cycles, elevated androgens, insulin resistance and chronic inflammation were sent away without a diagnosis because the scan looked clear. Women who presented with weight gain were told to lose weight, as if the weight were the cause rather than a symptom of the same dysfunction driving everything else. Women who presented without weight gain were told they couldn’t have PCOS at all. The name set the diagnostic criteria, and the diagnostic criteria excluded the very women the condition was affecting most.
What PMOS changes
Polyendocrine Metabolic Ovarian Syndrome places the hormonal and metabolic complexity of the condition at the centre of the diagnosis where it belongs. It signals that this is not a gynaecological issue with some hormonal features, but a complex multisystem condition with reproductive consequences.
That distinction changes what the right clinical response looks like. A condition named after ovarian cysts invites interventions targeted at the ovaries. A condition understood as polyendocrine and metabolic invites interventions that address hormonal regulation, insulin sensitivity, inflammatory load and the nutritional environment that drives all of them.
It also changes what the woman living with it is entitled to ask for — and what she is entitled to expect her medical team to understand.
What has not changed
The rename does not change the biology. Women with PMOS have the same condition they had last week under its previous name. The insulin resistance, the androgen excess, the disrupted ovulation, the inflammatory drivers — all of it remains. What changes is the framework through which it is understood and, over time, how it is investigated and treated.
It also does not change the gap between what the condition requires and what most women with it have been offered. A condition this complex responds to inputs that address its root causes — nutrition, blood sugar regulation, inflammatory load, hormonal support. That has always been true. The name change makes it harder to ignore.
The women who have spent years managing this condition through diet, blood sugar control, anti-inflammatory eating and lifestyle changes were already doing the right thing — because they understood, even without the language, that this was a hormonal and metabolic issue. The name change gives that work its proper framework.
What this means for fertility
PMOS is one of the most common causes of ovulatory dysfunction and fertility challenges in women of reproductive age. The hormonal and metabolic drivers that disrupt cycle regularity, impair egg quality and create a hostile environment for conception are the same drivers that respond — sometimes significantly — to nutritional and lifestyle intervention.
Insulin resistance affects the hormonal signals that trigger ovulation. Chronic low-grade inflammation impairs egg quality and the uterine environment. Elevated androgens disrupt follicular development. These are not incidental features of the condition — they are the condition. And they are responsive to what the body is being given to work with.
Understanding PMOS as a hormonal and metabolic condition rather than an ovarian one changes where the preparation work sits. It is not about managing symptoms at the point of treatment. It is about addressing the environment that determines whether ovulation, egg quality and implantation can happen at all.
At Now Baby we welcome this change and look forward to seeing the benefits it must bring to the patients affected.
Preparation before escalation — that is what this condition has always called for. The name finally says so.
